5-HT_1B/1D antagonists and depression

Bibliography

• MAES M, MELTZER HY: The serotonin hypothesis of major depression. In: Psychopharmacology: The fourth generation of progress. Bloom FE, Kupfer DJ (Eds.), Raven Press, New York (1995) 933–934.
   Google Scholar
• BLIER P, DE MONTIGNY C: Current advances and trendsin the treatment of depression. Trends Pharmacol Sci. (1994) 15:220–226.
   PubMed Web of Science ®Google Scholar
• FULLER RW, WONG DT: Serotonin re-uptake blockers invitro and in vivo. J. Clin. Psychopharmacol (1987) 7:365–435.
   PubMed Web of Science ®Google Scholar
• BOYER WF, FEIGHNER JP: The Efficacy of SSRIs in Depres-sion. Feighner JP, Boyer WF (Eds.), Wiley, Chichester (1991) 89–108.
   Google Scholar
• BRILEY M, MORET C: Neurobiological mechanisms in-volved in antidepressant therapies. Clin. Neuropharma-col. (1993) 16:387–400.
   PubMed Web of Science ®Google Scholar
• HJORTH S, SUCHOWSKI CS, GALLOWAY MP: Evidence for 5-HT autoreceptor-mediated, nerve impulse-inde-pendent control of 5-HT synthesis in the rat brain. Synapse (1995) 19:170–176
   PubMed Web of Science ®Google Scholar
• HOYER D, MIDDLEMISS DN: Species differences in the pharmacology of terminal 5-HT autoreceptors in mam-malian brain. Trends Pharmacol Sci. (1989) 10:130–132.
   PubMed Web of Science ®Google Scholar
• BLIER P, DE MONTIGNY C, CHAPUT Y: Modification ofthe serotonin 'stem by antidepressant treatments: implication for the therapeutic response in major de-pression. J. Clin. Psychopharmacol (1987) 7:245–355.
   Google Scholar
• BLIER P, DE MONTIGNY C, CHAPUT Y: A role of the serotonin system in the mechanism of action of antide-pressant treatments preclinical evidence. J. Clin. Psy-chiatry (1990) 51(014–21.
   Google Scholar
• CERVO L et al: TFMPP in the ventral segmental area reduces the effects of desipramine in the forced swim-ming test in rats: possible involvement of serotonin receptors. Eur. j Pharmacol (1989) 171:199–215.
   Google Scholar
• MARTIN P, PUECH A: Is there a relationship between 5-HT0 receptors and the mechanisms of action of antidepressant drugs in the learned helplessness para-digm in rats? Eur. J. Pharmacol (1991) 192:193–196.
   Google Scholar
• NEUMAIER JF, ROOT DC, HAMBLIN MW: Chronic fluoxet-ine reduces serotonin transporter mRNA and 5–11116 mRNA in a sequential manner in the rat dorsal raphe nucleus. Neuropsychopharmacol (1996) 15(5)515–522.
   Google Scholar
• GLENNON RA, WESTKAEMPER RB: 5-HT10 receptors: a serotonin receptor population for the 1990s. Drug News Perspect. (1993) 6:390–405.
   Google Scholar
• DOLBERG OT, SASSON Y, COHEN R, ZOHAR J: The rele-vance of behavioural probes in obsessive-compulsive disorders. Eur. Neuropsychopharmacol. (1995) 5:161–162.
   Google Scholar
• HARTIG PR, BRANCHEK TA, WEINSHANK RL: A subfamily of 5-HT1D receptor genes. Trends Pharmacol Sci. (1992) 13:152–159.
   PubMed Web of Science ®Google Scholar
• WEINSHANK RL, ZGOMBICK JM, MACCHI MJ, BRANCHEK TA, HARTIG PR: Human serotonin 1D receptor is en-coded by a subfamily of two distinct genes: 5-H TiDa and 5-HT1op. Proc. Natl. Acad. Sci. (1992) 89:3630–3634.
   PubMed Web of Science ®Google Scholar
• GLENNON RA et al: The binding of propanalol at 5-HTnip T355N mutant receptors may involve formation oftwo hydrogen bonds to asparagina. Mol. Pharmacol. (1996) 49:198–206.
   PubMed Web of Science ®Google Scholar
• OKSENBERGD et al.: A single amino-acid differenceconfers major pharmacological variation between hu-man and rodent 5-HT1s receptors. Nature (London) (1992) 360:161–163.
   PubMed Web of Science ®Google Scholar
• METCALF MA, MC GUFFIN RW, HAMBLIN MW: Conversionof the human 5-HT1op serotonin receptor to the rat 5-HT0 ligand-binding phenotype by TbP55Asn site directed mutagenes is . Biochem. Pharmacol. (1992) 44:1917–1920.
   PubMed Web of Science ®Google Scholar
• HARTIG PR, HOYER D, HUMPHREY PPA, MARTIN GR: Alignment of receptor nomenclature with the human genome: classification of 5-HT1s and 5-HT10 receptor subtypes. Trends Pharmacol. Sci. (1996) 17:103–105.
   PubMed Web of Science ®Google Scholar
• PAUWELS P: 5-HT1st10 receptor antagonists. General Pharmacology In Press.
   Google Scholar
• FERRARI MD, SAXENA PR: On serotonin and migraine: a clinical and pharmacological review. Cephalagia (1993) 13:151–165.
   PubMed Web of Science ®Google Scholar
• MOSKOWITZ MA: Neurogenic versus vascular mecha-nisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol. ScL (1992) 13:307–311.
   PubMed Web of Science ®Google Scholar
• PAUWELS PJ, PALMIER C, WURCH T, COLPAERT FC: Phar-macology of cloned human 5-HT10 receptor-mediated functional responses in stably transfected rat C6-glial cell lines: further evidence differentiating human 5-HT 10 and 5-HT1s receptors. Naunyn-Schmiedeberg'sArch. Pharmacol. (1996) 353:144–156.
   PubMed Web of Science ®Google Scholar
• PAUWELS PJ, TARDIF S, PALMIER C, WURCH T, COLPAERT FC: How efficacious are 5-HT1Bi10 receptors ligands at recombinant human 5-HT1s and 5-HT10 receptors: an answer from GTP-yS binding studies with stably trans-fected C6-glial cell lines. Neuropharmacol. (In Press).
   Google Scholar
• PAUWELS PJ, WURCH T, PALMIER C, COLPAERT FC: Pro-motion of cell growth but stimulation of cloned human 5-HT10 receptor sites in transfected C6-glial cells in highly sensitive to intrinsic activity at 5-HT1D receptors. Naunyn-Schmiedeberg's Arch. Pharmacol (1996) 354:136–144.
   Google Scholar
• TERRON JA: GR-127935 is a potent antagonist of the5-HTi-like receptor mediating contraction in the canine coronary artery. Eur. J. Pharmacol (1996) 300:109–112.
   PubMed Web of Science ®Google Scholar
• RAZZAQUE Z, LONGMORE J, HILL RG: Differences in theeffects of ketanserin and GR-127935 on 5-HT-receptor mediated responses in rabbit saphenous vein and guinea-pigjugular vein. Eur. j Pharmacol (1995) 283:199–206.
   PubMedGoogle Scholar
• MORET C, BRILEY M: The effect of terminal 5-HT autore-ceptor antagonists on 5-HT release in the guinea-pig brain. Br. J. Pharmacol (1995) 115:31P.
   PubMed Web of Science ®Google Scholar
• CHOPIN P, MORET C, BRILEY M: Neuropharmacology of 5-HT1s/10 ligands. Pharmacol. Ther. (1994) 62:385–405.
   PubMed Web of Science ®Google Scholar
• BRILEY M, CHOPIN P, MARIEN M, MORET C: Functionalneuropharmacology of compounds acting at 5-HT1si1D receptors. In: Handbook of Experimental Pharmacology - Serotoninergic Neurons and 5-HT receptors in the CNS Baumgarten HG, Gothert M (Eds.), Springer Verlag (1997) (In Press).
   Google Scholar
• SKINGLE M, HIGGINS GA, FENIUK W: Stimulation ofcentral 5-HT10 receptors causes hypothermia in the guinea-pig.j PsychopharmacoL (1994) 8:14–21.
   PubMed Web of Science ®Google Scholar
• HATCHER JP, SLADE PD, ROBERTS C, HAGAN JJ: 5-HT10 receptors mediate SKF 99101H-induced hypothermia in the guinea-pig. J. Psychopharmacol (1995) 9:234–241.
   PubMed Web of Science ®Google Scholar
• MORET C, BRILEY M: In vitro and in vivo activity of 1-(1-naphty0 piperazine at terminal 5-HT autoreceptors in guinea-pig brain. Naunyn-Schmiedeberg's Arch. Phar-macol. (1995) 351:377–384.
   PubMed Web of Science ®Google Scholar
• MORET C, BRILEY M: The unique effect of methiothep in on the terminal serotonin autoreceptor in the rat hy-pothalamus could be an example of inverse agonism. Psychopharmacol (1993) 7:331–337.
   Google Scholar
• PAUWELS PJ, REIHAUS E, PALMIER C et al.: Ketanserin differentiates between cloned human 5-HT1Da recep-tors and cloned human 5-HT1Dp, sheep and bovine caudate nucleus 5-HT1D receptor sites. Cell Phannacol. (1995) 2:183–191.
   Google Scholar
• BUHLEN M, FINK K, BOING C, GOTHERT M: Evidence for presynaptic location of inhibitory 5-HT1pp-like autore-ceptors in the guinea-pig brain cortex. Naunyn-Schmiedeberg's Arch. Pharmacol (1996) 353:281–289.
   Google Scholar
• PAUWELS PJ: Pharmacological properties of a putative 5-HT1st1p receptor antagonist GR 127,935. CNS DrugRev. (In Press).
   Google Scholar
• PAUWELS PJ, COLPAERT FC: The 5-HT1p receptor antago-nist GR 127935 is an agonist at cloned human 5-HTma receptor sites. Neuropharmacology (1995) 34:235–237.
   PubMedGoogle Scholar
• WATSON JM, BURTON MJ, PRICE GW, JONES BJ, MID-DLEMISS DN: GR-127935 acts as a partial agonist at recombinant human 5-HT1Da and 5-HT1Dp receptors. Eur. j Pharmacol. (1996) 314:365–372.
   PubMed Web of Science ®Google Scholar
• PAUWELS PJ: Unpublished results.
   Google Scholar
• CLITHEROW JW et aL: Evolution of a novel series of [(N,N-dim et hyl amino) pr opyl] - and pip er azinylbe n-zanilides as the first selective 5-HT1D antagonists. J. Med. Chem. (1994) 37:2253–2257.
   PubMed Web of Science ®Google Scholar
• WALSH DM, BEATTIE DT, CONNOR HE: The activity of 5-HT1p receptor ligands at cloned human 5-HT1Da and 5-HT1pp receptors. Eur. j Pharmacol (1995) 287:79–84.
   PubMed Web of Science ®Google Scholar
• GASTER L: Use of G-prote in coupled receptor modelling in the design of the first selective human 5-HT1B recep-tor inverse agonist. 3rd Annual Symposium on Random and Rational Drug Discovery via cOmbinatorial Chemistry and Structure-based Design, Geneva, Switzerland (Oct. 1996).
   Google Scholar
• BERNOTAS RC et al.: The synthesis of 4(1-piperaz-inyfibenzo[b]thiophenes as 5-HT1p antagonists with potential use as antianginal agents. Proceedings of the 25thNational Medical and Chemical Symposium, Ann Arbor (June 1996) Abstract 93.
   Google Scholar
• ROUSSELLE JC, MASSOT 0, DELEPIERRE M etal: Isolation and characterisation of an endogenous peptide from rat brain interacting specifically with the 5-Hl1s recep-tor subtypes. J. Biol. Chem. (1996) 271:726–735.
   PubMed Web of Science ®Google Scholar
• MASSOT 0 et al.: 5-hydroxyptryptamine-moduline, a new endogenous cerebral peptide, controls the sero-tonergic activity via its specific interaction with 5-HT1si1D receptors. Mol. Pharmacol (1996) 50:752–762.
   Google Scholar
• ARTIGAS F, ROMERO L, DE MONTIGNY C, BLIER P: Accel-eration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neuro-scL (1996) 19:378–383.
   PubMed Web of Science ®Google Scholar
• DAVIDSON C, STAMFORD JA: The effect of paroxetine on 5-HT efflux in the rat dorsal raphe nucleus is potenti-ated by both 5-HTIA and 5-Hr1Bt1p receptor antagonists. Neurosci. Lett. (1995) 188:41–44.
   PubMed Web of Science ®Google Scholar
• ROLLEMA H, CLARKE T, SPROUSE JS, SCHULZ DW: Com-bined administration of a 5-HT1D antagonist and a 5-HT re-uptake inhibitor synergistically increases 5-HT re- lease in guinea-pig hypothalamus in vivo. J. Neurochem. (1996) 67:2204–2207.
   PubMed Web of Science ®Google Scholar
• ISHIZUKA J et al.: Receptor-mediated autocrine growth-stimulatory effect of 5-HT on cultured human pancre-atic carcinoid cells. J. Cell. Physiol. (1992) 150:1–7.
   PubMed Web of Science ®Google Scholar
• CATTANEO MG, FESCE R, VICENTINI LM: Mitogenic effect of serotonin in human small cell lung carcinoma cells via both 5-HT1A and 5-HT1p receptors. Eur. J. PharmacoL (1995) 291:209–211.
   PubMed Web of Science ®Google Scholar
• PAUWELS PJ, WURCH T, AMOUREUX MC, PALMIER C,COLPAERT FC: Stimulation of cloned human 5-HT1pp receptor sites in stably transfected C6 glial cells pro-motes cell growth. J. Neurochem. (1996) 66:65–73.
   PubMed Web of Science ®Google Scholar